Seres Therapeutics to Participate in Three Upcoming November Conferences

Article Stock Quotes (1)

FREE Breaking News Alerts from StreetInsider.com!

StreetInsider.com Top Tickers, 8/21/2026

1. TGT
2. WMT
3. SPY
4. ROST
5. EL

6. ADI
7. LOW
8. MRK
9. BILL
10. NVDA

Get Alerts MCRB Hot Sheet

Price: $4.57 --0%

Overall Analyst Rating:
SELL (= Flat)

Join SI Premium – FREE

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Seres Therapeutics, Inc., (NASDAQ: MCRB) today announced that it will participate in each of the following upcoming healthcare conferences:

Stifel 2017 Healthcare Conference: A corporate overview will be presented on Tuesday, November 14 at 5:00 p.m. ET in New York, NY.
29th Annual Piper Jaffray Healthcare Conference: A corporate overview will be presented on Wednesday, November 29 at 10:30 a.m. ET in New York, NY.
Evercore ISI Biopharma Catalyst/Deep Dive Conference: Members of the management team will participate in one-on-one meetings on Thursday, November 30 in Boston, MA.

A live audio webcast of each presentation will be available under the “Investors and Media” section of Seres’ website. A replay of the presentation will become available approximately one hour after the event and will be archived for 21 days.

About Seres Therapeutics

Seres Therapeutics, Inc., is a leading microbiome therapeutics platform Company developing a novel class of biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome, where the natural state of bacterial diversity and function is imbalanced. Seres’ lead program, SER-109, has obtained Breakthrough Therapy and Orphan Drug designations from the U.S. Food and Drug Administration and is in Phase 3 development for multiply recurrent C. difficile infection. Seres’ clinical candidate SER-287 has successfully completed a Phase 1b study in patients with mild-to-moderate Ulcerative Colitis. Seres is also developing SER-262, the first ever synthetic microbiome therapeutic candidate, in a Phase 1b study in patients with primary C. difficile infection. For more information, please visit www.serestherapeutics.com. Follow us on Twitter @SeresTx.